description
Powered by Eupheria Biotech
Quality Level
product line
MISSION®
form
lyophilized powder
esiRNA cDNA target sequence
CCACTAGCCTTGGTCTGAGCTCTGACTGCATTGCTAGCTACTGTATAGGAGACTTAATTAGATCCCATAACCTAGAAGTGCCTGAATTGCTGCCTTGTGGATACCTTGTTGGAGATAATAACATCATCACTGTGAACCTCAAAGGGGTAGAAGAAAATAGTTTGGACAGTTTTGTTTTTGATACGCTGATTCCTAAACCAATTACCCAAAGGTACTTTAACTTGTTGATGGAGCATCACAGAATTATACTCTCAGGACCGAGTGGTACTGGAAAGACCTATTTGGCAAACAAACTTGCTGAATATGTAATAACCAAATCTGGAAGGAAAAAAACAGAGGATGCAATTGCCACTTTTAATGTGGACCACAAGTCAAGTAAGGAATTGCAACAATATCTAGCTAACCTGGCTGAACAGTGCAGTGCTGATAATAATGGAGTGGAGCTCCCAG
Ensembl | human accession no.
NCBI accession no.
shipped in
ambient
storage temp.
−20°C
Gene Information
human ... NAV3(89795)
General description
MISSION® esiRNA are endoribonuclease prepared siRNA. They are a heterogeneous mixture of siRNA that all target the same mRNA sequence. These multiple silencing triggers lead to highly-specific and effective gene silencing.
For additional details as well as to view all available esiRNA options, please visit SigmaAldrich.com/esiRNA.
For additional details as well as to view all available esiRNA options, please visit SigmaAldrich.com/esiRNA.
Legal Information
MISSION is a registered trademark of Merck KGaA, Darmstadt, Germany
存储类别
10 - Combustible liquids
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
Ryan Charles Pink et al.
Gynecologic oncology, 137(1), 143-151 (2015-01-13)
Ovarian cancer is the deadliest gynaecological cancer. A major contributor to the poor survival rate is the development of chemoresistance to platinum-based therapies such as cisplatin and carboplatin. Here we aimed to test the role of miRNAs in the acquisition
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| EHU072651-20UG | 04061828612017 |
| EHU072651-50UG | 04061828372522 |